Buprenorphine-Based Formulations for the Treatment of Opioid Use Disorder in Correctional Settings

Experience With and Rationale for Use of Specific Formulations Reduced risk of diversion and shorter duration for postadministration observation were noted as the primary reasons for providing the transmucosal film, and reasons why the respondent recommended the use of the formulation. [...] Experience With and Rationale for Use of Specific Formulations The respondent noted that the transmucosal film formulation is used to reduce the risk of diversion and reported that the formulation is well tolerated. [...] For patients who are on the transmucosal film formulation at the time of release from the correctional facility, the transmucosal tablet formulation is usually prescribed instead due to the lack of coverage of the transmucosal film formulation by the Ontario public drug programs. [...] The protocol also strongly recommends a urine drug test before initiating treatment.20 The respondent noted that patients on the transmucosal tablet, if found diverting the medication for the second time, are given the choice to switch to the depot injection or wean over a period of 2 weeks. [...] Experience With and Rationale for Use of Specific Formulations The respondents representing the health authority and the public drug plan noted reduced risk of diversion, ease of administration, reduced utilization of health care resources for administration, and elimination of Buprenorphine-Based Formulations for the Treatment of Opioid Use Disorder in Correctional Settings 30/42 Conclusion the n.